rethinkPeptides Search
Menu
Study breakdown

Peptide Binds MRP1 Flexible Linker to Reverse Cancer Multidrug Resistance

evidence
The takeaway

A designed peptide targeting the interdomain linker of MRP1 transporter reversed multidrug resistance in cancer cells by inhibiting drug efflux through a novel binding mechanism.

New target site

The flexible interdomain linker of MRP1 provides a novel peptide binding site for reversing multidrug resistance

What the researchers found

A peptide targeting MRP1's flexible interdomain linker inhibited drug efflux and reversed multidrug resistance by a novel mechanism distinct from substrate-based approaches.

Why it matters

Multidrug resistance causes most cancer treatment failures. Targeting transporter flexibility with peptides offers a fundamentally new approach.

How the study worked

Computational analysis of MRP1 interdomain linker dynamics, peptide design, molecular docking and dynamics simulations, and drug efflux functional assays.

What this study cannot tell us

In vitro evidence. Peptide stability and delivery in vivo not addressed. MRP1 is expressed in normal tissues, so selectivity needs optimization.

How to read the evidence

Computational and in vitro study establishing a novel mechanism. Early-stage requiring in vivo validation.

When this study was published

Published in 2025.

The bigger picture

Exploiting protein flexibility with peptides could be a general strategy for targeting "undruggable" proteins beyond cancer resistance.

Questions still open

  • Could this peptide be combined with chemotherapy in animal models?
  • Does the linker-binding mechanism apply to other ABC transporters?
  • Can the peptide be stabilized for systemic delivery?

Common questions

How does cancer resist chemotherapy?
Cancer cells pump drugs out using transporter proteins like MRP1. This study found a new way to block MRP1 using a peptide that locks it in a non-functional state, keeping drugs inside cancer cells.
Is this approach available for patients?
Not yet. It is an early-stage discovery that identifies a new target for drug design. Further development is needed before it could reach patients.

Read the original research

Reining in Multidrug Resistance Protein 1 via Binding Its Flexible Interdomain Linker with Sequence-Selective Peptide-Binding Nanoparticles.

Biomacromolecules

Citation

Ghosh, Avijit; Sharma, Mansi; Zhao, Yan. (2026). Reining in Multidrug Resistance Protein 1 via Binding Its Flexible Interdomain Linker with Sequence-Selective Peptide-Binding Nanoparticles.. Biomacromolecules. https://doi.org/10.1021/acs.biomac.5c02567